Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.

Losing weight with the help of a prescription weight loss drug continues to increase in popularity. According to recent KFF polls, about one in eight U.S. adults takes a GLP-1 medication for ...

Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price. | ...

Orforglipron led to greater weight loss than semaglutide tablets and could offer more effective oral alternative to jabs ...

Weight loss drugs are more popular than ever, even in cycling, but do the health benefits some are seeing outweigh the risks ...

“GLP‑1s have effectively created a third pillar of pharmacy spend and most employers don't yet have a mature playbook to manage it,” Conway said, adding that over half of employers now cite GLP‑1s as ...

Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lil | Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lilly’s Zepbound in a phase 3 weight loss study, further denting the Danish ...

Walgreens is wading into the self-pay GLP-1 space, going head-to-head with telehealth subscription offerings. | Walgreens is wading into the self-pay GLP-1 space, going head-to-head with telehealth ...

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

GLP-1 medications can be effective for weight loss and diabetes management but require lifestyle changes and can have severe ...

Novo Nordisk A/S plans to slash the US list prices for its blockbusters Wegovy and Ozempic next year as the drugmaker struggles to claw back a larger share of the obesity market.